Skip to main
FBRX

Forte Biosciences (FBRX) Stock Forecast & Price Target

Forte Biosciences (FBRX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Forte Biosciences Inc. is advancing its product candidate, FB-102, which shows promise in addressing various autoimmune disorders with significant unmet medical needs, potentially capturing market share in indications like graft-versus-host disease and type 1 diabetes. The increasing prescription growth for similar approved therapies in the market suggests a strong demand for effective treatments, reinforcing the outlook for FB-102's success. Additionally, the company's substantial rise in R&D expenses indicates a commitment to deepening clinical and manufacturing efforts, positioning Forte Biosciences well for future advancements and market positioning.

Bears say

Forte Biosciences faces significant risks due to intense market competition from existing and emerging therapies, which could hinder the company's ability to penetrate the market and maintain favorable pricing for its product candidate, FB-102. Furthermore, potential delays in clinical development, regulatory approvals, or commercialization timelines could extend development periods and lead to increased costs, which adversely affects financial stability. Additionally, the company's Phase Ib study limitations, including a low placebo control in comparison to competitors, suggest challenges in demonstrating the efficacy of FB-102, further contributing to a negative outlook for the stock.

Forte Biosciences (FBRX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Forte Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Forte Biosciences (FBRX) Forecast

Analysts have given Forte Biosciences (FBRX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Forte Biosciences (FBRX) has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Forte Biosciences (FBRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.